IntoCell인투셀

IntoCell's shares have fallen sharply over the past year while the company still reports large operating losses on small revenue.

IntoCell is a Korean antibody-drug conjugate platform company that earns revenue mainly from licensing its linker and payload technologies and early-stage drug candidates to global drugmakers. For the first half of 2026, filings show revenue of about ₩3.2B against an operating loss of about ₩8.9T, and cash of ₩10.6B against ₩10.0B of borrowings. The shares closed at ₩16,670, down 63.2% over one year and well below the 52-week high of ₩74,900.

What stands out

• Trailing revenue of about ₩3.2B is small against an operating loss of about ₩8.9T, giving an operating margin of roughly -279%.
• Revenue fell 20.9% in 2025 to about ₩2.3B, after about ₩2.9B in 2024, while the operating loss widened to about ₩10.3T.
• Free cash flow over the trailing period was about -₩10.4T, and the liabilities-to-equity ratio is 85.7%.
• Valuation is hard to anchor: the price-to-book ratio is 12.7 and there is no meaningful earnings-based P/E, while the dividend yield is 0%.
• Foreign ownership rose slightly to 4.8% from 4.4% sixty days earlier, but net 20-day flows were negative for foreign and institutional investors and positive for retail.

What to watch

• The full-year 2026 results and any further filings on the half-year report, which the data does not yet include in detail.
• The 'major management matter' filing dated 2026-07-22, whose content is not described in the data.
• Progress of the lead anti-B7-H3 ADC candidate (ITC-6146RO); the data does not include clinical timelines or new licensing deals, and no recent news headlines were provided.